Analyst Reco. Crinetics Pharmaceuticals, Inc.

Equities

CRNX

US22663K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 14/03/2026 am IST			5-day change	1st Jan Change
37.49 ^USD	+2.68%		-1.94%	-19.46%

27/02	Crinetics Pharmaceuticals, Inc., Q4 2025 Earnings Call, Feb 26, 2026
27/02	Crinetics Pharmaceuticals Q4 Loss Widens	MT

Analyst Reco.

13/01	Crinetics Shares Rise After Goldman Sachs Upgrade	MT
12/01	Goldman Sachs Upgrades Crinetics Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $67 From $45	MT
10/25/10	Goldman Sachs Initiates Crinetics Pharmaceuticals at Neutral With $36 Price Target	MT
25/25/25	Stifel Initiates Crinetics Pharmaceuticals at Buy With $60 Price Target	MT
11/25/11	TD Cowen Initiates Crinetics Pharmaceuticals at Buy	MT
04/25/04	Wolfe Research Initiates Coverage on Crinetics Pharmaceuticals With Peer Perform Rating	MT
22/25/22	Jefferies Upgrades Crinetics Pharmaceuticals to Buy From Hold, $55 Price Target	MT
09/24/09	Oppenheimer Trims Crinetics Pharmaceuticals Price Target to $73 From $74, Maintains Outperform Rating	MT
09/24/09	JPMorgan Raises Price Target on Crinetics Pharmaceuticals to $54 From $47, Maintains Overweight Rating	MT
04/24/04	Oppenheimer Raises Price Target on Crinetics Pharmaceuticals to $74 From $55, Maintains Outperform Rating	MT
23/24/23	Morgan Stanley Raises Price Target on Crinetics Pharmaceuticals to $70 From $50, Maintains Overweight Rating	MT
07/24/07	Piper Sandler Adjusts Price Target on Crinetics Pharmaceuticals to $97 From $56, Maintains Overweight Rating	MT
20/24/20	JMP Securities Adjusts Price Target on Crinetics Pharmaceuticals to $80 From $60, Maintains Market Outperform Rating	MT
20/24/20	Oppenheimer Raises Crinetics Pharmaceuticals Price Target to $55 From $54, Maintains Outperform Rating	MT
20/24/20	JonesTrading Raises Crinetics Pharmaceuticals' Price Target to $56 From $52, Maintains Buy Rating	MT
20/24/20	HC Wainwright Raises Crinetics Pharmaceuticals Price Target to $60 From $50, Maintains Buy Rating	MT
13/24/13	Oppenheimer Adjusts Crinetics Pharmaceuticals Price Target to $54 From $48, Maintains Outperform Rating	MT
08/24/08	HC Wainwright Adjusts Crinetics Pharmaceuticals Price Target to $50 From $42, Maintains Buy Rating	MT
06/24/06	Citigroup Initiates Crinetics Pharmaceuticals With Buy Rating, $68 Price Target	MT
04/24/04	Cantor Fitzgerald Adjusts Price Target on Crinetics Pharmaceuticals to $65 From $50, Maintains Overweight Rating	MT
29/24/29	Oppenheimer Raises Crinetics Pharmaceuticals Price Target to $48 From $46, Maintains Outperform Rating	MT
29/24/29	Baird Adjusts Crinetics Pharmaceuticals Price Target to $52 From $45, Maintains Outperform Rating	MT
11/23/11	Evercore ISI Adjusts Price Target on Crinetics Pharmaceuticals to $48 From $41, Maintains Outperform Rating	MT
11/23/11	Oppenheimer Adjusts Crinetics Pharmaceuticals Price Target to $46 From $40, Maintains Outperform Rating	MT
11/23/11	Baird Adjusts Crinetics Pharmaceuticals Price Target to $45 From $43, Maintains Outperform Rating	MT